August 17, 2022 News by Marta Figueiredo, PhD CNM-Au8 Lessens Vision Problems in RRMS Patients in Phase 2 Trial CNM-Au8, Clene Nanomedicineās experimental oral therapy, safely and effectively improves vision and neurological function in adults with stable relapsing-remitting multiple sclerosis (RRMS) and disease-related visual impairment. Those are the findings of the VISIONARY-MS Phase 2 clinical trial (NCT03536559), a proof-of-concept study that investigated CNM-Au8 in people with…
February 15, 2022 News by Steve Bryson, PhD VISIONARY-MS Trial of CNM-Au8 to End Early Due to Pandemic VISIONARY-MS, a Phase 2 clinical trial evaluating the safety and effectiveness of CNM-Au8 in people with relapsing multiple sclerosis (MS) with disease-related visual impairment, will conclude early due to COVID-19 pandemic-related challenges. The release of trial data is expected in the second half of this year, according to…
January 25, 2021 Columns by Ed Tobias MS News That Caught My Eye Last Week: Nanocrystals, ‘Cog Fog,’ Mapping MS, Ocrevus Clene Awaits US Patent Covering Gold Nanocrystalsā Use in Treating MS This is a different approach to MS treatment. It uses very tiny crystals to produce a chemical reaction. It is hoped that this reaction will protect neurons and help to generate myelin. So far, there have only been…
January 20, 2021 News by Marisa Wexler, MS Clene Awaits US Patent Covering Gold Nanocrystals’ Use in Treating MS Clene Nanomedicine has been notified it will be given a U.S. patent, as requested, covering an invention using the company’s already patented gold nanocrystals for the treatment of multiple sclerosis (MS). A Notice of Allowance was received by the company. These notices are issued by the U.S. Patent…
March 16, 2020 News by Ana Pena PhD #ACTRIMS2020 – CNM-Au8 a Potential ‘Breakthrough’ in MS Therapy, Clene CMO Says An investigational therapy that uses nanocrystals of gold to help the brain repair itself represents a breakthrough in the multiple sclerosis (MS) field, says Clene Nanomedicine‘s chief medical officer Robert Glanzman. Glanzman, MD, recently presented promising results at the ACTRIMS Forum 2020 indicating that Clene’s lead…
February 28, 2020 News by Ana Pena PhD #ACTRIMS2020 – Early Trial Data Support CNM-Au8 Improving Vision, Physical Abilities Clene Nanomedicine shared early results of the VISIONARY-MS trial, suggesting that CNM-Au8 āĀ an investigational remyelinating therapy ā leads to “notable” trends in better vision, as well as benefits in mobility and manual function in relapsing multiple sclerosisĀ (MS) patientsĀ with chronic vision problems.
February 13, 2020 News by Ana Pena PhD Gold Nanocrystals in Phase 2 Testing Show ‘Robust’ Remyelination Potential in Animal Models Clene Nanomedicine‘s remyelination therapy candidate, CNM-Au8, showed a “robust” ability to stimulate the production of new myelin and increase the number of myelin-wrapped nerve fibers in the brain and spinal cord of animals in models of demyelinating disease, allowing mice to recover motor skills, a study reports.
January 13, 2020 News by Marisa Wexler, MS First MS Patient Dosed in Phase 2 Trial of Potential Remyelinating Therapy CNM-Au8, Clene Announces The first participant has been dosed in the Phase 2 REPAIR-MS clinical trial examining the effects of CNM-Au8,Ā Clene Nanomedicine‘s investigational remyelinating therapy, on brain metabolism in people with multiple sclerosis (MS), the company announced. In MS, the immune system attacks myelin, the protective sheath that surrounds…
October 16, 2019 News by Alice MelĆ£o, MSc NMSS Awards $339K to Phase 2 Trial of Potential Remyelination Agent, Clene Nanomedicine Announces The National Multiple Sclerosis Society awarded more than $339,000 to Clene Nanomedicine to support clinical tests into its lead candidate CNM-Au8Ā in treatingĀ multiple sclerosis (MS) by protecting nerve cells and restoring myelin. The grant was awarded under the National MS Societyās Fast Forward program, which aims…
February 7, 2018 News by Iqra Mumal, MSc #ACTRIMS2018 – Clene Nanomedicine Presents Positive Results for MS Remyelinating Therapy Clene Nanomedicine says its pre-clinical studies demonstrate the remyelination effects of CNM-Au8, supporting its potential to treat multiple sclerosis (MS) and other demyelinating disorders. Clene presented its data in a session,Ā “Nanocrystalline Gold As a Novel Remyelination Therapeutic for Multiple Sclerosis,”Ā thatĀ took place at the third annual Americas…